- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharma Mar SAU (PHMR)
Assess today's live Pharma Mar SAU (PHMR) share price, performance and insights using our live Madrid: PHMR stock exchange data.
Analyse the historical data and Pharma Mar SAU share price performance charts on this page. Our technical summary section provides analysis on Pharma Mar share price buy/sell indicators using real-time data (or discuss the Pharma Mar (PHMR) stock price today with other investors in the Pharma Mar BME share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current BME PHMR share price (ISIN: ES0169501022) to enhance your trading decisions with our free investment tools and resources.
What Is the Pharma Mar SAU Share Price Today?
The Pharma Mar share price today is 79.350.
What Is the Stock Symbol for Pharma Mar SAU
The stock symbol (or 'ticker') for Pharma Mar SAU is "PHMR."
What Stock Exchange Does Pharma Mar SAU Trade On?
Pharma Mar SAU is listed and trades on the Madrid stock exchange.
Is Pharma Mar SAU a Good Stock to Buy?
Determining whether Pharma Mar SAU—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Pharma Mar SAU share price performance charts on this page. Our technical summary section provides analysis on Pharma Mar share price buy/sell indicators using real-time data (or discuss the Pharma Mar (PHMR) stock price today with other investors in the Pharma Mar BME share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current BME PHMR share price (ISIN: ES0169501022) to enhance your trading decisions with our free investment tools and resources.
What Is the Pharma Mar SAU Share Price Today?
The Pharma Mar share price today is 79.350.
What Is the Stock Symbol for Pharma Mar SAU
The stock symbol (or 'ticker') for Pharma Mar SAU is "PHMR."
What Stock Exchange Does Pharma Mar SAU Trade On?
Pharma Mar SAU is listed and trades on the Madrid stock exchange.
Is Pharma Mar SAU a Good Stock to Buy?
Determining whether Pharma Mar SAU—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
79.350
+1.550(+1.99%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
77.650
79.350
52 wk Range
65.000
105.800
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
77.65079.350
52 wk Range
65.000105.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.03%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.03%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
PHMR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
100.500
Upside
+26.65%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Pharma Mar Company Profile
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin that is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca, a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma. The company is also developing Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Compare PHMR to Peers and Sector
Metrics to compare | PHMR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHMRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 5.7x | −0.5x | |
PEG Ratio | 0.00 | −0.26 | 0.00 | |
Price/Book | 0.0x | 1.9x | 2.6x | |
Price / LTM Sales | 0.0x | 3.8x | 3.3x | |
Upside (Analyst Target) | 0.0% | 31.5% | 46.0% | |
Fair Value Upside | Unlock | 3.7% | 5.4% | Unlock |
Analyst Ratings
6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 100.500
(+26.65% Upside)
Earnings
Latest Release
Oct 30, 2025
EPS / Forecast
-0.13 / -0.12
Revenue / Forecast
35.70M / 34.60M
People Also Watch
FAQ
What Is the Pharma Mar (PHMR) Share Price Today?
The live Pharma Mar share price today is 79.350
What Stock Exchange Does Pharma Mar (PHMR) Trade On?
Pharma Mar is listed and trades on the Madrid Stock Exchange.
What Is the Ticker (Stock Symbol) for Pharma Mar?
The stock symbol (also called a 'ticker') for Pharma Mar is "PHMR."
Does Pharma Mar Pay Dividends? What’s The Current PHMR Dividend Yield?
Yes, PHMR Pays Dividends to its Shareholders. The current Pharma Mar dividend yield is 1.03%.
What Is the Current Pharma Mar Market Cap?
As of today, Pharma Mar market capitalisation is 1.360B.
What Is Pharma Mar's (PHMR) Earnings Per Share (TTM)?
The Pharma Mar EPS is currently 1.951 (Trailing Twelve Months).
When Is the Next Pharma Mar Earnings Date?
Pharma Mar's next earnings report will be released on 02/03/2026.
Is PHMR a Buy or Sell From a Technical Analyst Perspective?
Based on today's Pharma Mar moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Pharma Mar Stock Split?
Pharma Mar has split 7 times. (See the PHMR stock split history page for full effective split date and price information.)
How Many Employees Does Pharma Mar Have?
Pharma Mar has 500 employees.
What is the current trading status of Pharma Mar (PHMR)?
As of 18/02/2026, Pharma Mar (PHMR) is trading at a price of 79.350, with a previous close of 77.800. The stock has fluctuated within a day range of 77.650 to 79.350, while its 52-week range spans from 65.000 to 105.800.
What Is Pharma Mar (PHMR) Price Target According to Analysts?
The average 12-month price target for Pharma Mar is EUR100.500, with a high estimate of EUR120 and a low estimate of EUR75. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +26.65% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.